|
gptkbp:instanceOf
|
gptkb:drug
selective progesterone receptor modulator
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
2009
|
|
gptkbp:ATCCode
|
G03AD02
|
|
gptkbp:brand
|
gptkb:Ella
gptkb:Esmya
|
|
gptkbp:CASNumber
|
126784-99-4
|
|
gptkbp:chemicalClass
|
gptkb:Corticosteroid
|
|
gptkbp:contraindication
|
pregnancy
severe liver disease
|
|
gptkbp:developedBy
|
HRA Pharma
|
|
gptkbp:discoveredBy
|
gptkb:National_Institutes_of_Health
|
|
gptkbp:drugClass
|
hormonal medication
|
|
gptkbp:eliminationHalfLife
|
32 hours
|
|
gptkbp:hasMolecularFormula
|
C30H37NO4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ulipristal acetate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
progesterone receptor antagonist
partial agonist at progesterone receptor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D
X
contraindicated
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
135565893
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
headache
menstrual irregularities
|
|
gptkbp:synonym
|
CDB-2914
VA2914
|
|
gptkbp:UNII
|
YVI317YW2X
|
|
gptkbp:usedFor
|
oral contraceptive
treatment of uterine fibroids
|
|
gptkbp:bfsParent
|
gptkb:Emergency_Contraceptive_Pill
|
|
gptkbp:bfsLayer
|
7
|